Frontiers in Psychiatry
January 17, 2019
Santiago Castro-Zaballa, Matías Cavelli, Joaquín González et al.
Cognitive processes are carried out during wakefulness by means of extensive interactions between cortical and subcortical areas. In psychiatric conditions, such as psychosis, these processes are altered. Interestingly, REM sleep where most dreams occurs, shares electrophysiological, pharmacological, and neurochemical features with psychosis. Because of this fact, REM sleep is considered a...
IBRO Reports
January 16, 2019
Michael Zhang, Kennett D. Radford, Mercedes Y. Driscoll et al.
34 citations
Ketamine, a multimodal dissociative anesthetic, is a powerful analgesic administered following trauma due to its hemodynamic and respiratory stability. However, ketamine can cause hallucination and dissociation which may adversely impact traumatic memory after an injury. The effects of ketamine on proteins implicated in neural plasticity are unclear due to different doses, routes, and timing of...
Neuroimage
January 11, 2019
Michele A. Colombo, Martino Napolitani, Melanie Boly et al.
359 citations
Despite the absence of responsiveness during anesthesia, conscious experience may persist. However, reliable, easily acquirable and interpretable neurophysiological markers of the presence of consciousness in unresponsive states are still missing. A promising marker is based on the decay-rate of the power spectral density (PSD) of the resting EEG. We acquired resting electroencephalogram (EEG)...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 10, 2019
Nerea Llamosas, Laura Perez-Caballero, Esther Berrocoso et al.
Accumulating evidence indicates that the antidepressant effects of ketamine are, in part, mediated by an increase in the AMPA receptor-mediated neurotransmission in depression related areas, such as the prefrontal cortex (PFC). Therefore, activity in PFC-projecting areas related to major depression, such as the dorsal raphe nucleus (DR), may also be modulated by ketamine. We used whole-cell...
American Journal of Psychiatry
January 4, 2019
Satoshi Deyama, Eunyoung Bang, Eric S. Wohleb et al.
100 citations
OBJECTIVE: -methyl-d-aspartate receptor antagonist ketamine produces rapid and sustained antidepressant actions even in patients with treatment-resistant depression. Vascular endothelial growth factor (VEGF) has been implicated in the effects of conventional monoamine-based antidepressants, but the role of VEGF in the rapid antidepressant actions of ketamine remains unclear. The authors...
Neuropsychopharmacology
January 2019
Mark Jeremy Hunt, Natalie E Adams, Władysław Średniawa et al.
High-frequency neuronal population oscillations (HFO, 130-180 Hz) are robustly potentiated by subanesthetic doses of ketamine. This frequency band has been recorded in functionally and neuroanatomically diverse cortical and subcortical regions, notably ventral striatal areas. However, the locus of generation remains largely unknown. There is compelling evidence that olfactory regions can drive...
African journal of emergency medicine : Revue africaine de la medecine d'urgence
2019
Sarah Villegas, Sebastian Suarez, Joseph Owuor et al.
Five of the 7.2 billion people on earth have limited access to emergency and essential surgical procedures. The lack of safe, affordable and timely anaesthesia services are primary barriers to universal surgical coverage. The objective of this study was to assess intraoperative awareness when the 'Every Second Matters for Emergency and Essential Surgery - Ketamine' (ESM-Ketamine) package was...
Chronic Stress
2019
Ginetta Collo, Laura Cavalleri, Emilio Merlo Pich
The mechanisms underlying the antidepressant effects of ketamine in treatment-resistant depression are only partially understood. Reactivation of neural plasticity in prefrontal cortex has been considered critical in mediating the effects of standard antidepressants, but in treatment-resistant depression patients with severe anhedonia, other components of the affected brain circuits, for...
Pharmacology, Biochemistry, and Behavior
2019
Nian-nian Huang, Dongyu Hua, Gaofeng Zhan et al.
ABSTRACT Ketamine, an N‐methyl‐d‐aspartic acid receptor (NMDAR) antagonist, elicits rapid‐acting and sustained antidepressant effects in treatment‐resistant depressed patients. Accumulating evidence suggests that gut microbiota via the gut‐brain axis play a role in the pathogenesis of depression, thereby contributing to the antidepressant actions of certain compounds. Here we investigated the...
Chronic Stress
2019
Katherine N Wright, Devin P Hagarty, C. Strong et al.
Background Ketamine has rapid antidepressant effects and shows great promise as a novel treatment for depression, but its limitations including its abuse potential are poorly understood. Given that the prevalence of depression is twice as high in women as in men and that depression and substance use disorders are highly comorbid, we hypothesized that a sex-specific responsivity to behavioral...